Breaking News: NervGen Reaches Milestone in Groundbreaking Spinal Cord Injury Study
Topline data from the chronic cohort is expected in Q2 2025
Institutional Review Board (IRB) protocol amendment changes approved, and screening has been initiated for subacute cohort
This news release constitutes a “designated news release” for the purposes of NervGen’s prospectus supplement dated December 19, 2024 to its short form base shelf prospectus dated November 25, 2024. Vancouver, British Columbia–(Newsfile Corp. – January 2, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has enrolled the 20th and final subject in the chronic cohort of its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial (NCT05965700) evaluating its lead candidate, NVG-291, in individuals with spinal cord injury (SCI).
Spinal cord injuries have long been a challenging area of medicine to treat, often leaving patients with lifelong disabilities. NervGen’s groundbreaking study aims to change the landscape of SCI treatment by developing innovative therapies that target neurorestoration. The enrollment of the final subject in the chronic cohort marks a significant milestone in the progress of this research, bringing hope to those affected by spinal cord injuries and their families.
The approval of Institutional Review Board protocol amendment changes and the initiation of screening for the subacute cohort are crucial steps towards advancing the study to the next phase. With topline data from the chronic cohort expected in Q2 2025, the medical community eagerly anticipates the results that could potentially revolutionize the treatment of spinal cord injuries.
How will this affect me?
If you or a loved one has been affected by a spinal cord injury, the advancements made in NervGen’s study could offer new hope for improved treatment options and potential neurorestoration. Stay informed about the latest developments in this groundbreaking research to see how it may impact the lives of those with SCI in the future.
How will this affect the world?
The success of NervGen’s study could have far-reaching implications for the healthcare industry and individuals worldwide. By introducing innovative neurorestorative therapies for spinal cord injuries, this research has the potential to enhance the quality of life for patients, reduce healthcare costs, and drive progress in the field of regenerative medicine.
Conclusion
NervGen’s milestone in reaching the final subject enrollment in the chronic cohort of its spinal cord injury study is a significant achievement that holds promise for the future of SCI treatment. With topline data expected to be released in Q2 2025, the medical community eagerly awaits the results that could potentially transform the lives of individuals living with spinal cord injuries. Stay tuned for more updates on this groundbreaking research that aims to bring hope and healing to those in need.
